[go: up one dir, main page]

WO2008008841A3 - Utilisation de dérivés de benzimidazoles pour le traitement et/ou la prévention de désordres autoimmunitaires - Google Patents

Utilisation de dérivés de benzimidazoles pour le traitement et/ou la prévention de désordres autoimmunitaires Download PDF

Info

Publication number
WO2008008841A3
WO2008008841A3 PCT/US2007/073266 US2007073266W WO2008008841A3 WO 2008008841 A3 WO2008008841 A3 WO 2008008841A3 US 2007073266 W US2007073266 W US 2007073266W WO 2008008841 A3 WO2008008841 A3 WO 2008008841A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune disorders
benzimidazole derivatives
prevention
treatment
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073266
Other languages
English (en)
Other versions
WO2008008841A2 (fr
Inventor
Jagadish C Sircar
Mark L Richards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of WO2008008841A2 publication Critical patent/WO2008008841A2/fr
Publication of WO2008008841A3 publication Critical patent/WO2008008841A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne sous ses aspects préférés, le traitement et/ou la prévention de désordres autoimmunitaires, tels que le lupus érythémateux disséminé (SLE) et la sclérose en plaques, en utilisant une famille de dérivés de benzimidazoles.
PCT/US2007/073266 2006-07-14 2007-07-11 Utilisation de dérivés de benzimidazoles pour le traitement et/ou la prévention de désordres autoimmunitaires Ceased WO2008008841A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83104106P 2006-07-14 2006-07-14
US60/831,041 2006-07-14

Publications (2)

Publication Number Publication Date
WO2008008841A2 WO2008008841A2 (fr) 2008-01-17
WO2008008841A3 true WO2008008841A3 (fr) 2008-05-29

Family

ID=38924149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073266 Ceased WO2008008841A2 (fr) 2006-07-14 2007-07-11 Utilisation de dérivés de benzimidazoles pour le traitement et/ou la prévention de désordres autoimmunitaires

Country Status (1)

Country Link
WO (1) WO2008008841A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2393861C1 (ru) * 2009-01-15 2010-07-10 Аверин Константин Михайлович Композиция для лечения рассеянного склероза (варианты)
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
US10538371B2 (en) 2018-03-28 2020-01-21 In-Tech Enterprise Ltd. Container security system
CN116114657B (zh) * 2022-10-11 2024-06-11 上海交通大学医学院附属瑞金医院 一种红斑狼疮样小鼠模型的构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006117A1 (en) * 2002-02-15 2004-01-08 Schering Aktiengesellschaft Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
US20050256179A1 (en) * 2003-08-08 2005-11-17 Sircar Jagadish C Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006117A1 (en) * 2002-02-15 2004-01-08 Schering Aktiengesellschaft Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
US20050256179A1 (en) * 2003-08-08 2005-11-17 Sircar Jagadish C Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Also Published As

Publication number Publication date
WO2008008841A2 (fr) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008019115A3 (fr) Formulations pour l'administration parentérale de composés et leurs utilisations
WO2008011392A8 (fr) Antagonistes ccr1 de proline urée utilisés pour des maladies auto-immunes et l'inflammation
WO2008097561A8 (fr) Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
WO2007100617A3 (fr) Composés à base d'imidazole, compositions les comprenant et leurs méthodes d'utilisation
WO2008070670A3 (fr) Formulations de topiramate à libération immédiate améliorées
WO2007120980A3 (fr) Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
WO2010060937A3 (fr) Combinaisons inhibitrices hsp90
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2008048991A3 (fr) Composés organiques
WO2007126957A3 (fr) Nouveaux composés
WO2007111994A3 (fr) Composés et méthodes pour traitement de troubles associés à un stress du réticulum endoplasmique
WO2006119295A3 (fr) Compositions et methodes de traitement de maladies neurodegeneratives
IL200766A0 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
WO2008039520A3 (fr) Composés cycliques condensés pour utilisations associées à l'inflammation et aux troubles immunitaires
WO2007137071A3 (fr) Compositions de r(+) et s(-) pramipéxole et procédés d'utilisation de celles-ci
WO2007084857A3 (fr) Procédés et compositions de traitement de troubles prolifératifs cellulaires
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
WO2009085889A3 (fr) Compositions et procédés pour réduire ou empêcher la perte d'eau par la peau
TN2010000155A1 (en) Organic compounds
WO2009009417A3 (fr) Compositions pharmaceutiques et procédés pour prévenir, traiter ou inhiber des maladies, des troubles ou des affections inflammatoires cutanés et des maladies, des troubles ou des affections associés à un appauvrissement en collagène
WO2007112121A3 (fr) Composés à base de tétracyline et procédés de traitement
WO2008033449A3 (fr) Composés pour le traitement de l'angiogenèse
WO2006128143A3 (fr) Composes a base d'hydantoine
WO2012009447A3 (fr) Voie camp/pka/hdac5 et ses utilisations
WO2010037095A3 (fr) Agents et procédés pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799493

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC

122 Ep: pct application non-entry in european phase

Ref document number: 07799493

Country of ref document: EP

Kind code of ref document: A2